For research use only. Not for therapeutic Use.
Oxotremorine M iodide is a potent and non-selective muscarinic acetylcholine receptor (mAChR) agonist. Oxotremorine M iodide potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms[1].
Oxotremorine M iodide (0.1, 0.3, 1, 3, 10, 30 μM) inhibits KCNQ2/3 currents in the concentration-dependence[2].
Oxotremorine M iodide elicits a robust phosphoinositide response characterized with an EC50 of 0.22 μM. Oxotremorine M iodide has EC50s of 0.36, 0.52, 1.62, and 1.48 μM for wild-type, M2, M3, and M2/M3 knockout mice, respectively[3].
Oxotremorine M iodide (0.5 mg/kg; s.c.) increases Ddopamine (DA) release in the medial prefrontal cortex (mPFC) and has no effect in the nucleus accumbens (NAC) in male sprague-dawley albino rats weighing 250-350 g[4].
| Catalog Number | I011675 |
| CAS Number | 3854-04-4 |
| Synonyms | trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium;iodide |
| Molecular Formula | C11H19IN2O |
| Purity | ≥95% |
| InChI | InChI=1S/C11H19N2O.HI/c1-13(2,3)10-5-4-8-12-9-6-7-11(12)14;/h6-10H2,1-3H3;1H/q+1;/p-1 |
| InChIKey | VVLMSCJCXMBGDI-UHFFFAOYSA-M |
| SMILES | C[N+](C)(C)CC#CCN1CCCC1=O.[I-] |
| Reference | [1]. Zwart R, et al. Oxotremorine-M potentiates NMDA receptors by muscarinic receptor dependent and independentmechanisms. Biochem Biophys Res Commun. 2018 Jan 1;495(1):481-486. [2]. Zwart R, et al. A novel muscarinic receptor-independent mechanism of KCNQ2/3 potassium channel blockadeby Oxotremorine-M. Eur J Pharmacol. 2016 Nov 15;791:221-228. [3]. Tran JA, et al. Differential coupling of muscarinic M1, M2, and M3 receptors to phosphoinositide hydrolysis in urinary bladder and longitudinal muscle of the ileum of the mouse. J Pharmacol Exp Ther. 2006 Aug;318(2):649-56. Epub 2006 May 4. [4]. Ichikawa J, et al. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 2002 Dec 20;958(1):176-84. |
